Literature DB >> 35165469

[Clinicopathological study in 28 cases of oral basaloid squamous cell carcinomas].

C X Zhou1, Z Zhou1, Y Zhang1, X X Liu1, Y Gao1.   

Abstract

OBJECTIVE: To investigate the clinicopathologic features and prognostic factors in oral basaloid squamous cell carcinoma.
METHODS: Retrospective analysis of oral basaloid squamous cell carcinomas patients who underwent tumor resection during the period from January 2002 to December 2020 in the authors' hospital, especially the clinicopathologic characteristics of 28 cases with confirmed diagnosis and follow-up data. Immunohistochemistry was performed to define the helpful markers for differentiation diagnosis. The factors influencing the prognosis were evaluated based on Kaplan-Meier method.
RESULTS: The tongue and mouth floor (11 cases, 39.3%) were the most frequently involved sites, followed by gingiva (6 cases, 21.4%), buccal (5 cases, 17.9%), palate (4 cases, 14.3%), and oropharynx (2 cases, 7.1%). The majority of basaloid squamous cell carcinomas were in advanced stage, with 12 cases in stage Ⅱ and 16 cases in stages Ⅲ-Ⅳ. Twelve of 28 patients were identified to have cervical lymph node metastasis, which was confirmed by histopathological examination. The incidence rate of lymph node metastasis was 42.9% (12/28). Nine tumors recurred, with one metastasized to the lung. At the meantime, the 28 conventional squamous cell carcinomas were matched with the same stage, among which 13 cases were identified with cervical lymph node metastasis. The incidence rate of lymph node metastasis was 46.4% (13/28). Five cases recurred, with two cases that metastasized to the lung and one to the brain. The 5-year overall survival rates of the basaloid squamous cell carcinoma and conventional squamous cell carcinoma patients were 54.6% and 53.8%, respectively. Histopathologically, basaloid cells consisted of tumor islands without evident keratinization but frequently with comedo-like necrosis within the tumor islands. CK5/6 and P63 exhibited strongly positive in all the 28 cases, whereas neuroendocrine markers, CgA and Syn, were negative. Eight cases positively expressed P16; one case showed focal SOX10 positive but CK7 negative.
CONCLUSION: The majority of oral basaloid squamous cell carcinomas present in advanced stage with a high tendency to lymph node metastasis, but the overall survival rates are not significantly different from conventional squamous cell carcinomas matched with the same stage. The human papilloma virus (HPV), as HPV-positivity rate is high, correlates to good prognosis. In addition, CK7 & SOX10 immunohistochemistry could contribute to differential diagnosis for basaloid squamous cell carcinoma with solid adenoid cystic carcinoma.

Entities:  

Keywords:  Adenoid cystic carcinoma; Human papilloma virus; P16; Squamous cell carcinoma

Mesh:

Year:  2022        PMID: 35165469      PMCID: PMC8860647     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  23 in total

Review 1.  Basaloid squamous cell carcinoma of the head and neck: role of HPV and implication in treatment and prognosis.

Authors:  J Thariat; C Badoual; C Faure; C Butori; P Y Marcy; C A Righini
Journal:  J Clin Pathol       Date:  2010-10       Impact factor: 3.411

Review 2.  Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.

Authors:  Masato Nakaguro; Yuichiro Tada; William C Faquin; Peter M Sadow; Lori J Wirth; Toshitaka Nagao
Journal:  Cancer Cytopathol       Date:  2020-05-18       Impact factor: 5.284

3.  Prognostic significance of basaloid squamous cell carcinoma in head and neck cancer.

Authors:  Okechukwu R Linton; Michael G Moore; Joseph S Brigance; Chris A Gordon; Don-John Summerlin; Mark W McDonald
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2013-12       Impact factor: 6.223

4.  Histopathologic findings of HPV and p16 positive HNSCC.

Authors:  Abie H Mendelsohn; Chi K Lai; I Peter Shintaku; David A Elashoff; Steven M Dubinett; Elliot Abemayor; Maie A St John
Journal:  Laryngoscope       Date:  2010-09       Impact factor: 3.325

5.  Differential expression of claudin‑4, occludin, SOX2 and proliferating cell nuclear antigen between basaloid squamous cell carcinoma and squamous cell carcinoma.

Authors:  Fuyuki Sato; Ujjal K Bhawal; Itaru Tojyo; Shigeyuki Fujita; Shin-Ichi Murata; Yasuteru Muragaki
Journal:  Mol Med Rep       Date:  2019-06-24       Impact factor: 2.952

6.  Course and prognosis of basaloid squamous cell carcinoma of the head and neck: a case-control study of 62 patients.

Authors:  Edouard Soriano; Claire Faure; Sylvie Lantuejoul; Emile Reyt; Michel Bolla; Elisabeth Brambilla; Christian A Righini
Journal:  Eur J Cancer       Date:  2007-12-21       Impact factor: 9.162

7.  A clinicopathologic study on basaloid squamous cell carcinoma in the oral and maxillofacial region.

Authors:  G-Y Yu; Y Gao; X Peng; Y Chen; F-Y Zhao; M-J Wu
Journal:  Int J Oral Maxillofac Surg       Date:  2008-07-15       Impact factor: 2.789

Review 8.  Human Papillomavirus and Potentially Relevant Biomarkers in Tonsillar and Base of Tongue Squamous Cell Carcinoma.

Authors:  Anders Näsman; Cinzia Bersani; David Lindquist; Juan Du; Torbjörn Ramqvist; Tina Dalianis
Journal:  Anticancer Res       Date:  2017-10       Impact factor: 2.480

9.  A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.

Authors:  Eline Boon; Miranda Bel; Wim van Boxtel; Winette T A van der Graaf; Robert J J van Es; Simone E J Eerenstein; Robert J Baatenburg de Jong; Michiel W M van den Brekel; Lilly-Ann van der Velden; Max J H Witjes; Ann Hoeben; Stefan M Willems; Elisabeth Bloemena; Laura A Smit; Sjoukje F Oosting; Marianne A Jonker; Uta E Flucke; Carla M L van Herpen
Journal:  Int J Cancer       Date:  2018-03-23       Impact factor: 7.396

10.  PLAG1, SOX10, and Myb Expression in Benign and Malignant Salivary Gland Neoplasms.

Authors:  Ji Hyun Lee; Hye Ju Kang; Chong Woo Yoo; Weon Seo Park; Jun Sun Ryu; Yuh-Seog Jung; Sung Weon Choi; Joo Yong Park; Nayoung Han
Journal:  J Pathol Transl Med       Date:  2018-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.